Anne Brooks

Anne Brooks is a seasoned executive with extensive experience in the pharmaceutical and biotechnology sectors, currently serving as Senior Vice President of US Commercial at Iovance Biotherapeutics, Inc., where responsibilities include overseeing the cell therapy account team and leading the US launch of AMTAGVI (lifileucel), the first FDA-approved cell therapy for advanced melanoma. Prior roles at Iovance encompassed Interim Chief Commercial Officer and SVP of Global Commercial Strategy and Marketing, where Brooks played a pivotal role in product development and regulatory filings. Previous experience includes senior marketing positions at Teva Pharmaceuticals, Cephalon, Gilead Sciences, and Bristol-Myers Squibb, contributing to significant oncology and HIV product launches and marketing strategies. Brooks holds an MBA in Marketing from The Wharton School and a BA in Journalism and Mass Communication from the University of North Carolina at Chapel Hill.